Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 366-369

  Maheshwari, S ^a   Kassim, A ^b   Yeh, R F ^c   Domm, J ^d   Calder, C ^d   Evans, M ^d   Manes, B ^d   Bruce, K ^e   Brown, V ^d   Ho, R ^d   Frangoul, H ^d   Yang, E ^f  

^a INOVA CHILDREN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Pharmacokinetics Laboratory   (United States)

^d MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

busulfan; pharmacokinetics; sickle cell disease; transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; THYMOCYTE ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HLA SYSTEM; HUMAN; MALE; NEUTROPHIL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIBLING; SICKLE CELL ANEMIA; STEADY STATE; THROMBOCYTE; TREATMENT OUTCOME; AGE; ANEMIA, SICKLE CELL; BONE MARROW TRANSPLANTATION; CHEMISTRY; CYTOLOGY; DISEASE FREE SURVIVAL; INFANT;

ADOLESCENT; AGE FACTORS; ANEMIA, SICKLE CELL; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; NEUTROPHILS; SIBLINGS; TREATMENT OUTCOME;

EID: 84904243199     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.188     Document Type: Article

References (19)

1. Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011; 117: 772-779.
2. Locatelli F, Pagliara D. Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease. Pediatr Blood Cancer 2012; 59: 372-376.
3. Vermylen C, Cornu G, Ferster A, Brichard B, Ninane J, Ferrant A et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1-6.
4. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369-376.
5. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110: 2749-2756.
6. Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137: 479-485.
7. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925-930.
8. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
9. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 167-173.
10. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20: 543-549.
11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
12. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
13. Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1013-1018.
14. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-987.
15. Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socie G, Mechinaud F et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 2012; 58: 90-97.
16. Nagasawa M, Mitsuiki N, Ono T, Takagi M, Oda H, Yasuhara M et al. Pharmaco-kinetic monitoring is still required for intravenous busulfan in SCT for small children. Int J Hematol 2010; 91: 728-730.
17. Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012; 48: 3063-3072.
18. McPherson ME, Hutcherson D, Olson E, Haight AE, Horan J, Chiang KY. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011; 46: 27-33.
19. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16: 263-272.